		USD	INR (In Thousands)	USD	INR (In Thousands)
		As a		As	
	Notes	31 Marc	h 2019	31 Marc	ch 2018
ASSETS					
Non-current assets					
Financial assets					
Long-term loans and advances	1 _	3,690	255	3,823	249
Total non-current assets		3,690	255	3,823	249
Current assets					
Financial assets		0.4.5	. <del>.</del>	0.45	60
Cash and cash equivalents	2	945	65	945	62
Other current assets	3	3,960	274	1,901	124
Total current assets	_	4,905	339	2,846	185
Total assets	_	8,595	594	6,669	435
EQUITY AND LIABILITIES					
Equity					
Equity share capital	4	13,71,501	68,559	13,71,501	68,559
Other equity	_	(14,31,248)	(72,692)	(14,17,512)	(71,558)
Total equity	_	(59,747)	(4,133)	(46,011)	(2,999)
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	5	68,342	4,727	52,678	3,434
Total current liabilities	<u> </u>	68,342	4,727	52,678	3,434
Total liabilities	_	68,342	4,727	52,678	3,434
Total equity and liabilities	_	8,595	594	6,669	435

Benny Thomas

**General Manager - Finance** 

Place: Noida

Date: 17 May, 2019

### Jubilant Biosys Singapore Pte. Limited Statement of Profit and Loss for the year ended 31 March 2019

		USD	INR (In	USD	INR (In
			Thousands)		Thousands)
Particulars	Notes	For the y	ear ended	For the year ended	
		31 Mar	ech 2019	31 Marc	ch 2018
Expenses					
Other expenses	6	13,736	968	12,618	812
Total expenses	_	13,736	968	12,618	812
Loss before tax		(13,736)	(968)	(12,618)	(812)
Tax expense					
- Current tax	_				
Total tax expense	_	-	-	-	-
Loss after tax		(13,736)	(968)	(12,618)	(812)
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Exchange differences on translation of foreign operations			(166)		(21)
Other comprehensive income for the year, net of tax	_	-	(166)	-	(21)
Total comprehensive loss for the year	_	(13,736)	(1,134)	(12,618)	(833)

Benny Thomas General Manager - Finance

Place: Noida

Date: 17 May, 2019

		INI	R (' In Thousands)
a) Equity share capital	Note	No. of shares	Amount
Balance as at 1 April 2017	4	13,71,501	68,559
Changes in equity share capital during the year			
Balance as at 31 March 2018	4	13,71,501	68,559
Changes in equity share capital during the year			
Balance as at 31 March 2019	4	13,71,501	68,559

#### b) Other Equity

	Reserves and surplus						
	Retained	Exchange differnces on translation of foreign operations		al			
	USD	INR (In	INR (In	USD	INR (In		
		Thousands)	Thousands)		Thousands)		
Balance as at 1 April 2017	(14,04,894)	(76,713)	5,988	(14,04,894)	(70,725)		
Loss for the year	(12,618)	(812)	-	(12,618)	(812)		
Exchange differences on translation of							
foreign operations	-	-	(21)	-	(21)		
Balance as at 31 March 2018	(14,17,512)	(77,525)	5,967	(14,17,512)	(71,558)		
Loss for the year	(13,736)	(968)	-	(13,736)	(968)		
Exchange differences on translation of	( - ) /	( /		( - ) )	()		
foreign operations	-	-	(166)	-	(166)		
Balance as at 31 March 2019	(14,31,248)	(78,493)	5,801	(14,31,248)	(72,692)		

Benny Thomas General Manager - Finance

Place: Noida Date: 17 May, 2019

## Jubilant Biosys Singapore Pte Limited Statement of Cash Flows for the year ended 31 March 2019

	USD	INR (In	USD	INR (In
	,	Thousands)		Thousands)
	For the year	ar ended	For the ye	ar ended
Particulars	31 Marc	h 2019	31 Marc	eh 2018
A. Cash flow from operating activities				
Loss before tax	(13,736)	(968)	(12,618)	(812)
Operating cash flow before working capital changes				
(Increase) in other current assets and loan and advances	(1,928)	(134)	(354)	(23)
Increase in trade payables	15,664	1,089	12,972	837
Cash generated from operations	_	(12)	-	2
Income tax paid (net of refund)	-	-	-	-
Net cash from/(used in) used in operating activities	-	(12)	-	2
B. Effect of exchange rate changes		16		(2)
Net decrease in cash and cash equivalents (A+B)	-	4	-	_
Add: cash and cash equivalents at the beginning of year	945	62	945	61
Cash and cash equivalents at the end of the year	945	66	945	62
-				

Benny Thomas General Manager - Finance

Place: Noida

Date: 17 May, 2019

## Jubilant Biosys Singapore Pte. Limited Notes to the financial statements for the year ended 31 March 2019

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31	March 2019	As at 31	March 2018
Note 1. Long term loan and advances				
Security deposits	3,690	255	3,823	249
	3,690	255	3,823	249
Note 2. Cash and cash equivalent Balances with banks:				
- On current accounts	945	65	945	62
	945	65	945	62
Note 3. Other current assets				
Prepaid expenses	3,960	274	1,901	124
•	3,960	274	1,901	124

#### Note 4: Equity share capital

	USD	INR (In	USD	INR (In
	As at 31 M	Thousands) arch 2019	As at 31	Thousands) March 2018
<b>Issued, subscribed and paid up share capital</b> 1,371,501 (31 March 2018: 1,371,501 equity shares with no par value	13,71,501	68,559	13,71,501	68,559
	13,71,501	68,559	13,71,501	68,559

#### 1) Movement in equity share capital

				INR (' In
	Note	No. of shares	USD	Thousands)
Balance as at 1 April 2017	4	13,71,501	13,71,501	68,559
Changes in equity share capital during the year				-
Balance as at 31 March 2018	4	13,71,501	13,71,501	68,559
Changes in equity share capital during the year				-
Balance as at 31 March 2019	4	13,71,501	13,71,501	68,559

<sup>2)</sup> The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

4) The details of shareholders holding more than 5% shares in the company: -

	As	at	As	at
	31 March 2019		31 March 2018	
	No. of shares	% holding in the class	No. of shares	% holding in the class
Name of the Shareholder				
Jubilant Biosys (BVI) Limited	13,71,501	100%	13,71,501	100%

<sup>3)</sup> In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

# Jubilant Biosys Singapore Pte. Limited Notes to the financial statements for the year ended 31 March 2019

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31	March 2019	As at 31	March 2018
Note 5. Trade payables				
Trade payables-others	68,342	4,727	52,678	3,434
	68,342	4,727	52,678	3,434
Note 6. Other expenses				
Auditors remuneration	4,150	290	4,159	268
Legal, professional and consultancy charges	9,378	663	8,703	560
Foreign exchange loss/(gain)	208	15	(244)	(16)
	13,736	968	12,618	812